27 JUL 2023 | EU | New indication alert: AZ’s Soliris® (eculizumab) approved to treat gMG in children aged six to 17 AstraZeneca announced that the EMA has approved Soliris®...
BioBlast w/e 28 Jul 23
read more
‘Repair’ defence to patent infringement and the perils of hindsight bias
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 21 Jul 23
21 JUL 2023 | EU | CHMP adopts positive opinion for three biosimilars The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Naomi Pearce is the 2023 Lawyers Weekly IP Partner of the Year
We are excited to announce that Naomi Pearce, (CEO, Executive, Lawyer, Patent & Trade Mark Attorney), founder of Pearce IP, was crowned the 2023 Intellectual Property...
Make priority your priority – ToolGen loses priority battle for CRISPR patent
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 14 Jul 23
14 JUL 2023 | EU | EMA confirms acceptance of Intas’ MAA for its ustekinemab (Stelara®) biosimilar Intas Pharmaceuticals announced that the European Medicine Agency (EMA) has...
Pearce IP’s Naomi Pearce Finalist for IP Partner of the Year – 2023 Australian Law Awards
We are proud to announce that Naomi Pearce, (Executive, Lawyer, Patent & Trade Mark Attorney), founder of Pearce IP, is a finalist for the award of Intellectual Property...
Trade Marked Goods Not ‘A Moveable Target’ in a Patent Claim
Australian and New Zealand patent examiners typically frown upon the use of trade marks in claims. Primarily, a trade mark is a sign that denotes origin, and a trade mark-branded...
BioBlast w/e 07 Jul 23
07 JUL 2023 | IN | CuraTeQ Biologics enters into exclusive licence agreement with BioFactura, Inc to commercialise its biosimilar to Janssen’s Stelara® (ustekinumab) Aurobindo...
Boutique IP Firm Pearce IP promotes Chris Vindurampulle PhD to Executive
Boutique IP firm Pearce IP announces the promotion of Patent & Trade Mark Attorney Dr Chris Vindurampulle to Executive, with effect from 1 July 2023. Founder and CEO Naomi...
Good news for inventors of computer technologies – Perram J redefines manner of manufacture following Aristocrat
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
Pearce IP and its Leaders Ranked in IAM Patent 1000 2023 for Litigation and Prosecution
We are delighted to announce that Pearce IP, together with three of its leaders have been ranked in IAM Patent 1000 in 2023. IAM Patent 1000 “shines a spotlight on the firms and...
The $325M Question | Commonwealth Disappointed in Landmark Appeal Court Damages Case
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 30 Jun 23
01 JUL 2023 | US | Organon and Samsung Bioepis announce launch of Hadlima®, biosimilar to AbbVie’s Humira® (adalimumab) Organon and Samsung Bioepis announced that Hadlima®,...
BioBlast w/e 23 Jun 23
22 JUN 2023 | JP | ASLAN enters strategic licence with Zenyaku Kogyo to exclusively develop and commercialise novel eblasakimab ASLAN Pharmaceuticals announced that it entered an...
BREAKING NEWS: COMMONWEALTH SANOFI DAMAGES DECISION DELIVERED BY FULL COURT: Sanofi avoids damages payment to the Commonwealth in Clopidogrel decision
The Full Federal Court handed down its decision this morning in the longstanding dispute as to whether the Commonwealth can claim under the “undertaking as to damages” a patentee...
Cannabidiol PBS listing expanded: Chiesi secures second PBS reimbursed indication for Epidyolex®
The PBS listing for Chiesi’s Epidyolex®, an oral cannabidiol, was expanded on 1 June 2023 to include treatment of seizures in patients with Lennoz-Gastatut Syndrome (LGS)....
‘Selection’ amendments allowable before Patent Office in failed BioNTech opposition
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast f/e 16 Jun 23
16 JUN 2023 | BR | Bio-Thera Solutions enter agreement for distribution of BAT2206 (ustekinumab biosimilar to Stelara®) in Brazil BusinessWire reports that Bio-Thera Solutions...
I’ll cry about it later – Katy Perry appeals AU trade mark loss
Katy Perry has appealed a Federal Court decision handed down on 21 April 2023 by Markovic J in Australia (Taylor v Killer Queen, LLC (No 5) [2023] FCA 364) that found her...
No issue estoppel in Australian Patent Office proceedings
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
Use of a Trade Mark in Patent Claims not limited to the Trade Marked Goods so no Lack of Clarity
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 2 Jun 23
01 JUN 2023 | EU | New indication alert: EC approves Novartis’ Cosentyx® (secukinumab) for HS Novartis announced that the European Commission (EC) has approved its Cosentyx®...
Schlam dunk – Federal Court makes Norwich Pharmacal orders against third party new employer
Jackson J in Austin Engineering Pty Ltd v Podulova & Ors [2023] FCA 419 issued interlocutory Norwich Pharmacal orders against ex-employee Anastasis Podulova and her new...
Recent BioBlast® Updates
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.